What is the price target for PROF stock?
5 analysts have analysed PROF and the average price target is 11.6 USD. This implies a price increase of 94.91% is expected in the next year compared to the current price of 5.95.
PROFOUND MEDICAL CORP (PROF) Forecast, Price Target & Analyst Ratings
NASDAQ:PROF • CA74319B5027
Current stock price
5.95 USD
-0.24 (-3.88%)
At close:
5.95 USD
0 (0%)
After Hours:
Analyst forecast overview
View the latest analyst price targets, stock forecast, EPS estimates, revenue projections, revisions, full estimates, rating distribution and upgrades/downgrades for PROFOUND MEDICAL CORP (PROF).
Forecast Snapshot
Next Earnings Forecast
Earnings Estimate- Release Date
- May 6, 2026
- Period
- Q1 / 2026
- EPS Estimate
- -$0.23
- Revenue Estimate
- 5.05M
Price Target Details & History
Consensus Price Target and Range
Mean target
$11.60
Upside
+ 94.91%
From current price of $5.95 to mean target of $11.60, Based on 5 analyst forecasts
Low
$11.48
Median
$11.60
High
$11.94
Price Target Revisions
1 Month
2.04%
3 Months
2.21%
Price Target Summary
5 Wall Street analysts provided a forecast for the next 12 months for PROF. The average price target is 11.6 USD. This implies a price increase of 94.91% is expected in the next year compared to the current price of 5.95.
The average price target has been revised upward by 2.21% in the past 3 months.
Analyst Ratings & History
Current Analyst Ratings
Analyst Ratings History
Analyst Ratings Consensus
ChartMill Buy Consensus
80.00%
PROF was analyzed by 5 analysts. The buy percentage consensus is at 80. So analysts seem to be have mildly positive about PROF.
In the previous month the buy percentage consensus was at a similar level.
Only 5 analysts analyzed PROF. So this is just the average opinion of a couple of analysts.
Recent Upgrades & Downgrades
| Date | Firm | Action | From → To |
|---|---|---|---|
| 2026-01-07 | Lake Street | Maintains | Buy -> Buy |
| 2025-04-23 | Lake Street | Maintains | Buy -> Buy |
| 2024-07-16 | Stifel | Upgrade | Hold -> Buy |
| 2024-03-11 | Alliance Global Partners | Maintains | Buy -> Buy |
| 2024-03-08 | Stifel | Maintains | Hold -> Hold |
| 2024-01-04 | Alliance Global Partners | Maintains | Buy -> Buy |
| 2023-11-28 | Stifel | Initiate | Hold |
| 2023-08-04 | Raymond James | Downgrade | Strong Buy -> Outperform |
| 2023-05-11 | TD Cowen | Maintains | Outperform |
| 2023-05-11 | Alliance Global Partners | Maintains | Buy |
| 2023-03-21 | Jefferies | Downgrade | Buy -> Equal-Weight |
| 2022-11-04 | Raymond James | Upgrade | Outperform -> Strong Buy |
| 2022-03-07 | Cowen & Co. | Maintains | Outperform |
| 2022-02-22 | Raymond James | Downgrade | Strong Buy -> Outperform |
| 2021-07-28 | Raymond James Financial | Initiate | Strong Buy |
| 2021-05-13 | Raymond James Financial | Upgrade | Strong-Buy |
| 2021-03-10 | Raymond James Financial | Initiate | STRONG BUY |
| 2021-02-26 | Raymond James Financial | Reiterate | Strong Buy |
Next Earnings Forecast Details
Next Earnings Details
- Release Date
- May 6, 2026
- Period
- Q1 / 2026
- EPS Estimate
- -$0.23
- Revenue Estimate
- 5.05M
- Revenue Q2Q
- 92.67%
- EPS Q2Q
- 36.88%
- Number of Analysts
- 4
Next Earnings Revisions
Revenue (1 Month)
-33.33%
Revenue (3 Months)
-32.43%
EPS (1 Month)
2.17%
EPS (3 Months)
15.09%
Next Earnings Summary
PROF is expected to report earnings on 5/6/2026. The consensus EPS estimate for the next earnings is -0.23 USD and the consensus revenue estimate is 5.05M USD.
The next earnings revenue estimate has been revised downward by 32.43% in the past 3 months. Downward revisions are a negative sign and indicate that analysts are more pessimistic about the next earnings compared to 3 months ago.
Full Analyst Estimates 2026 - 2033
Yearly Earnings Per Share (EPS), Revenue, EBIT, EBITDA and Operating Margin Analyst Estimates
| 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY % growth | 7.199M 7.75% | 10.68M 48.35% | 16.098M 50.73% | 34.677M 115.41% | 55.702M 60.63% | 78.446M 40.83% | 194.58M 148.04% | 265.02M 36.20% | 333.85M 25.97% | 411.57M 23.28% | 498.56M 21.14% | |
| EBITDA YoY % growth | -27.47M 1.89% | -32.126M -16.95% | -40.694M -26.67% | -29.24M 28.15% | -14.342M 50.95% | 26.768M 286.64% | 71.993M 168.95% | 109.98M 52.76% | 143.56M 30.53% | 181.09M 26.14% | 229.34M 26.64% | |
| EBIT YoY % growth | -28.616M 3.33% | -33.062M -15.54% | -41.254M -24.78% | -33.364M 19.13% | -23.129M 30.68% | -404K 98.25% | 12.216M 3,123.76% | 32.464M 165.75% | N/A | N/A | N/A | |
| Operating Margin | -397.50% | -309.57% | -256.27% | -96.21% | -41.52% | -0.52% | 6.28% | 12.25% | N/A | N/A | N/A | |
| EPS YoY % growth | -1.35 2.17% | -1.12 17.04% | -1.41 -25.89% | -1.08 23.59% | -0.69 36.25% | -0.07 89.72% | 1.34 1,992.27% | 2.06 54.06% | 2.70 31.36% | 3.42 26.50% | 5.22 52.63% |
All data in USD
Quarterly Earnings Per Share (EPS), Revenue, EBIT and EBITDA Analyst Estimates
| Q1 / 26 | Q2 / 26 | Q3 / 26 | Q4 / 26 | Q1 / 27 | Q2 / 27 | Q3 / 27 | Q4 / 27 | |
|---|---|---|---|---|---|---|---|---|
| EPS Q2Q % growth | -0.23 36.88% | -0.22 57.27% | -0.20 22.31% | -0.17 38.28% | -0.19 17.78% | -0.17 22.73% | -0.13 35.00% | -0.09 45.45% |
| Revenue Q2Q % growth | 5.05M 92.67% | 6.464M 192.36% | 8.484M 60.41% | 10.403M 74.05% | 10.268M 103.33% | 11.305M 74.89% | 13.517M 59.32% | 15.609M 50.04% |
| EBITDA Q2Q % growth | -7.676M 30.24% | -6.262M 53.62% | -5.555M 34.35% | -4.141M 39.18% | -5.151M 32.89% | -4.646M 25.81% | -2.828M 49.09% | -1.111M 73.17% |
| EBIT Q2Q % growth | -9.09M 18.59% | -8.383M 39.28% | -7.525M 15.58% | -6.363M 13.65% | -7.02M 22.78% | -6.565M 21.69% | -5.101M 32.21% | -3.485M 45.24% |
All data in USD
Yearly Earnings Per Share (EPS) and Revenue Trends vs Historical Data
Long Term Forward Growth Forecast Summary
Long Term EPS Growth (CAGR)
EPS Next 3 Year
24.93%
EPS Next 5 Year
28.18%
Long Term Revenue Growth (CAGR)
Revenue Next 3 Year
65.72%
Revenue Next 5 Year
72.73%
Long Term EBIT Growth (CAGR)
EBIT Next 3 Year
37.90%
EBIT Next 5 Year
35.43%
PROFOUND MEDICAL CORP / PROF Forecast FAQ
Can you provide the upcoming earnings date for PROFOUND MEDICAL CORP?
PROFOUND MEDICAL CORP (PROF) will report earnings on 2026-05-06.
What are the consensus estimates for PROF stock next earnings?
The consensus EPS estimate for the next earnings of PROFOUND MEDICAL CORP (PROF) is -0.23 USD and the consensus revenue estimate is 5.05M USD.
Can you provide the analyst count for PROFOUND MEDICAL CORP stock?
The number of analysts covering PROFOUND MEDICAL CORP (PROF) is 5.